Trevi Therapeutics reports Q3 EPS (8c), consensus (10c)

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026. Company ended the third quarter of 2025 with $194.9M in cash, cash equivalents and marketable securities with expected cash runway into 2028. “Following positive clinical data for both IPF chronic cough and RCC earlier this year, our strong progress continues. We have been executing on the studies necessary to advance our IPF chronic cough program and are on track to submit our End-of-Phase 2 meeting request to the FDA in the fourth quarter,” said Jennifer Good, President and CEO of Trevi Therapeutics (TRVI). “We look forward to discussing our development program with the FDA and are building a robust and comprehensive package for those discussions. Our overall corporate strategy is built on a clear path for growth, focused on specialty indications in chronic cough that currently have no approved therapies in the U.S. and have significant negative impacts on the quality of life of the patients with these conditions.”